Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis
- 96 Downloads
Pneumocystis carinii pneumonia (PCP) is a rare form of pneumonia associated with immune-suppression. It is common in patients with AIDS and with a CD4 count of less than 200 cells/mm3. We report a case of PCP secondary to immune-suppression in a 41-year-old man with psoriatic arthritis being treated with the immune-modulatory agent etanercept.
Diagnosis of PCP was made histologically using tissue obtained via transbronchial biopsy.
There was a good response to standard treatment with high-dose co-trimoxazole.
This report highlights a recognised but previously unreported complication of etanercept.
KeywordsPneumocystis carinii Etanercept Psoriatic arthritis Grocott’s silver stain Co-trimoxazole
- 1.The National Institute of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia (1990) Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 323:1500–1504CrossRefGoogle Scholar